HIV

Additionally, the ITT-E population showed both treatment arms showing a high proportion of participants with plasma HIV-1 RNA c/mL with dolutegravir/lamivudine demonstrating non-inferior virologic suppression to the TAF-based regimen.

The medication receives the approval after it was shown to be more effective than daily tenofovir disoproxil fumarate with emtricitabine tablets.

Because Biktarvy is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.

Khalili and his colleagues have completed preclinical studies that have shown that EBT-101 can effectively excise HIV proviral DNA from the genomes of different cells and tissues, including HIV-infected human cells and cells and tissues of humanized mice.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

The findings, published in the Journal of the American Heart Association, add to a list of cardiac risks experienced by patients with HIV.

Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.

Collaborative efforts between patients, physicians, pharmacists, and other essential personnel can further promote the effectiveness of PrEP regimens.

Brad McElya, PharmD, director of specialty health solutions at Walgreens, discusses the critical role pharmacists play in providing HIV prevention drugs in communities across America.

Specialty pharmacists’ roles have grown in new and exciting ways in recent years, and those changes have directly impacted health outcomes for all specialty patients, including patients with HIV.

Analyzing how off-target antibodies may be undermining HIV vaccine prototypes allows for design improvements.

Multimorbidity, health-related quality of life, and stigma and discrimination continue to be major issues for people living with HIV, including those who have achieved viral suppression, according to a consensus statement from a multidisciplinary panel of HIV experts published in Nature Communications.

Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.

A generic TDF/FTC costs as low as $30 per month, compared with about $1800 per month for branded TAF/FTC

The investigators noted that the levels of islatravir in peripheral blood mononuclear cells remained above the efficacy pharmacokinetics threshold for PrEP for both doses studied (60 mg and 120 mg) for 8 weeks following the last study dose.

Workflow in the clinic and the pharmacy are critical for the implementation of a new and novel medication therapy, such as cabotegravir-rilpivirine.

A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.

The drug also resulted in zero cases of virologic failure and no development of resistance in virologically suppressed adults with HIV-1 who have not previously experienced virologic failure.

In one program, hospital pharmacists received alerts whenever an antiretroviral was prescribed in the emergency department, enabling prompt action.

Because viral clearance is compromised if HIV is allowed to replicate for an extended period of time—resulting in extensive damage to the immune system—controlling HIV with antiretroviral therapy may be critical to preventing this type of viral evolution in SARS-CoV-2 in patients with advanced HIV.

Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.

Investigators have identified metabolic and glycomic signatures in blood samples of post-treatment controllers, a rare population of HIV-infected individuals who can naturally sustain viral suppression after antiretroviral therapy.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

June 27 is National HIV Testing Day, so Pharmacy Times interviewed Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, on his perspective on the critical role of testing all sexually active individuals who may be at risk for HIV.

Investigators have found bNAbs for HIV, hepatitis C, and influenza, among others.